BIO on CNBC: IPR System Weakens Medical Innovation

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on CNBC’s Fast Money where he discussed our industries concerns’ with the U.S. Patent and Trademark Office’s patent challenge system known as Inter Partes Review (IPR).

Dr. Cohen concisely explained this complicated and rapidly evolving issue and made clear why Congress must quickly address abuses to the IPR system within current Patent reform legislation.

Regrettably, this system that was designed by Congress just a few years ago to help protect innovations is being abused by outside interests. BIO is deeply concerned by these well documented abuses of the IPR system and what that means for future investment in innovation and ultimately the ability of patients to have access to new therapies in the future.

Accordingly, BIO stands with an array of industries that require the value of dependable and enforceable patents, over 100 patient organizations, the life sciences venture capital community and seventy nine U.S. House of Representatives Members in calling for improvements to patent reform legislation that properly address current abuses in the patent system.

If you haven’t done so yet, please visit to register your concerns with the current IPR system with Congress.

Filed under: Patently BIOtech, , , , , , , ,